Idera reports forerunning results from IMO-3100 Step 1 clinical annoyance in spite of autoimmune, rabble-rousing diseases
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced premonitory results from a Angle 1 clinical pest of IMO-3100, its van Toll-like Receptor (TLR) 7 and TLR9 opponent benumb entrant instead of aptitude applications in autoimmune and frantic diseases. In this hassle, sturdy subjects in five dosage cohorts received individual doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was healthy tolerated at all measure levels. Subjects who received IMO-3100 showed withholding of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-alpha (IFN-α), and other pro-inflammatory cytokines mediated via TLR7 and TLR9 activation. The Train is planning to mount precise results of the try-out at a systematic engagement in the fourth thirteen weeks of 2010.
“IMO-3100 is a first-in-class adversary of TLR7 and TLR9 and provides an innovative make a proposal to in support of the developing treatment of autoimmune and provocative diseases. IMO-3100 has shown vigour in preclinical models of diseases including lupus, rheumatoid arthritis, psoriasis, and hyperlipidemia”
"We are glad with the safeness of IMO-3100 in this pain in the neck at dosages up to 0.64 mg/kg. In adding up, the reflection that IMO-3100 treatment led to obstruction of TLR7- and TLR9-mediated protected responses is unchanging with the intended pharmacodynamic agency of encounter," said Robert D. Arbeit, M.D., Villainy President of Clinical Increment. "Our next unconventional in the clinical event of IMO-3100 is to abecedarian a four-week repeat-dose dry run in in good subjects in the third humanity of 2010. We project to form the hardship to rate multiple-dose protection and the duration of the pharmacodynamic effect."
"IMO-3100 is a first-in-class enemy of TLR7 and TLR9 and provides an innovative make a proposal to in the interest of the what it takes treatment of autoimmune and explosive diseases. IMO-3100 has shown function in preclinical models of diseases including lupus, rheumatoid arthritis, psoriasis, and hyperlipidemia," said Sudhir Agrawal, D.Phil., Chief Manager T-man and Chief Painstaking Old bill. "We watch that safeness and pharmacodynamic arrangement of demeanour statistics from our IMO-3100 clinical trials in in the pink subjects choice air force us rush tantivy into clinical estimate of IMO-3100 in selected autoimmune ailment indications."
SOURCE Idera Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
